Cross-Tier and Mechanism-Agnostic Interventions
Some interventions target multiple mechanisms simultaneously, or address disease burden independently of a specific mechanism. These are listed separately to avoid duplication across tier sections.
| Treatment | Primary targets | Energy | Evidence |
|---|---|---|---|
| Pacing / energy envelope management | Prevents Tier 2 amplification cascade; avoids PEM-driven worsening | A | Core clinical practice; validated by 2-day CPET (Keller et al. 2024) |
| Sleep optimization (environment + schedule) | Tiers 1+2: CNS recovery, immune regulation, ANS restoration | A | Clinical consensus |
| CPAP (if OSA comorbid) | Tier 2: sleep fragmentation β; dysautonomia β; treats comorbidity only | A/B | Clinical; does not resolve core ME/CFS |
| Mediterranean / anti-inflammatory diet | Tier 2: oxidative stress β, gut barrier β, mast cell load β | A | Lifestyle; no ME/CFS RCT |
| MCT oil | Ketone substrate; bypasses glycolytic bottleneck | A | Supplement; no ME/CFS RCT |
| Rapamycin (sirolimus) | Tier 1 (immune brake) + Tier 2 (mitophagy, epigenetic aging β) | B/C | Pilot β ~34% ITT response |
| GLP-1 agonists (semaglutide) | Neuroinflammation β + metabolic + vagal tone; genetic pathway enrichment (PrecisionLife (Gardner 2026)) | B/C | Experimental; Long COVID signal; no ME/CFS data; liraglutide preferred for CNS endpoints (see GLP-1 Receptor Agonists: Subgroup-Stratified Repurposing Candidate) |
| LOLA (L-ornithine L-aspartate) | Ammonia detoxification + mitochondrial substrate | A/B | Experimental |
| Perrin technique (lymphatic drainage) | Glymphatic clearance of CNS neurotoxins; ANS normalization | A | Very low evidence; mechanistically plausible |
| CA inhibitors (acetazolamide / topiramate) | CSF volume reduction / intracranial pressure normalization; topiramate adds TRPV1βmast cell modulation | B/C | IIH Class I evidence (acetazolamide); no ME/CFS trial; cognitive worsening concern (Mitchell et al. 2025); (Medow and Stewart 2024); see Synergistic CSF Volume Reduction and Neurolymphatic Drainage |
| Acupuncture | ANS, neuroinflammation, pain; see Tier 2: Amplifier Mechanisms | A/B | Pilot RCTs |
| Melatonin | Sleep + antioxidant + immune modulation; start 0.5 mg β higher doses may worsen sleep | A/B | Clinical use |
| B-vitamin complex (B1, B2, B6, B9, B12) | Methylation; mitochondrial cofactors; neurotransmitter synthesis | A | Clinical use; MTHFR genotype relevant for B9/B12 |
| Tocilizumab (anti-IL-6R) | Cytokine dysregulation (Tier 1/2 boundary) | C | Off-label; 1 case report only |
| Amifampridin (3,4-DAP) | Neuromuscular junction; voltage-gated CaΒ²βΊ channel modulation | B | Experimental |
| Graded motor imagery / mirror therapy | Central sensitization; pain-movement coupling (strong evidence in CRPS; no ME/CFS RCT) | A | High in CRPS; absent in ME/CFS |
References
Gardner, Steve. 2026. βGLP-1 RAs: Hype, Hope and Hidden Dangers.β https://investinme.org/brmec15-stevegardner.shtml.
Keller, Betsy A, Candace N Receno, Carl J Franconi, Sebastian Harenberg, Jared Stevens, Xiangling Mao, Staci R Stevens, et al. 2024. βCardiopulmonary and Metabolic Responses During a 2-Day CPET in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Translating Reduced Oxygen Consumption to Impairment Status to Treatment Considerations.β Journal of Translational Medicine 22 (1): 627. https://doi.org/10.1186/s12967-024-05410-5.
Medow, Marvin S., and Julian M. Stewart. 2024. βEffects of Acetazolamide and Phenylephrine on Neurocognitive Function During Head-up Tilt in ME/CFS with POTS.β American Journal of Physiology: Regulatory, Integrative and Comparative Physiology 326 (6): R599β608. https://doi.org/10.1152/ajpregu.00071.2024.
Mitchell, James L., Nirali Bhatt, Christopher Weckerle, Michael Wicklund, Michael Smith, James Pott, and Jonathan D. Bodle. 2025. βA Randomized Sequential Crossover Study Comparing Acetazolamide, Amiloride, Furosemide, Spironolactone, and Topiramate in Idiopathic Intracranial Hypertension.β Headache 65 (2): 258β68. https://doi.org/10.1111/head.14897.